NCT01388036

Genetic Determinants of Hemodynamic Response to Esmolol

A Study in Healthy Subjects to Evaluate Genetic Determinants of the Variability in Hemodynamic Response to Esmolol

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD and hypertension. However, there is large interindividual variability in the response to beta blockers. The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.

Conditions

• Decrease in Heart Rate Below Baseline Value

Interventions

Type	Name	Description
DRUG	esmolol	consecutive infusions of esmolol and normal saline (placebo)

Timeline

• Start date: 2011-07-01
• Primary completion: 2015-05-01
• First posted: 2011-07-06
• Last updated: 2011-07-06

Locations

1 site across 1 country: Israel